Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
28 April 2015Next earnings report:
07 February 2025Last dividends:
N/ANext dividends:
N/APrice
pre-market | 11 min agoDividend
Analysts recommendations
Institutional Ownership
VKTX Latest News
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) concerning possible violations of federal securities laws. On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to climb 9% during intraday trading on November 4, 2024.
The biotech's liver-disease treatment is also viewed as best-in-class, earning it a full slate of buy ratings from analysts.
3 Things You Need to Know if You Buy Viking Therapeutics Today
Is It Too Late to Buy Viking Therapeutics Stock?
NEW YORK, NY / ACCESSWIRE / November 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) concerning possible violations of federal securities laws. On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to climb 9% during intraday trading on November 4, 2024.
Mergers and acquisitions could make a comeback with Trump headed back to Washington.
NEW YORK CITY, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) concerning possible violations of federal securities laws. On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to climb 9% during intraday trading on November 4, 2024.
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) concerning possible violations of federal securities laws. On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to climb 9% during intraday trading on November 4, 2024.
What type of business is Viking Therapeutics?
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
What sector is Viking Therapeutics in?
Viking Therapeutics is in the Healthcare sector
What industry is Viking Therapeutics in?
Viking Therapeutics is in the Biotechnology industry
What country is Viking Therapeutics from?
Viking Therapeutics is headquartered in United States
When did Viking Therapeutics go public?
Viking Therapeutics initial public offering (IPO) was on 28 April 2015
What is Viking Therapeutics website?
https://www.vikingtherapeutics.com
Is Viking Therapeutics in the S&P 500?
No, Viking Therapeutics is not included in the S&P 500 index
Is Viking Therapeutics in the NASDAQ 100?
No, Viking Therapeutics is not included in the NASDAQ 100 index
Is Viking Therapeutics in the Dow Jones?
No, Viking Therapeutics is not included in the Dow Jones index
When was Viking Therapeutics the previous earnings report?
No data
When does Viking Therapeutics earnings report?
The next expected earnings date for Viking Therapeutics is 07 February 2025